Enexa Bio
Enexa Bio is engineering precision small molecules for autoimmune disease, led by a biomarker-driven lupus nephritis program. With compelling data and clear target engagement, Enexa Bio is building a scalable pipeline across systemic immunology.
General Prognostics Inc.
General Prognostics (GPx) develops clinically validated digital biomarkers that transform consumer wearables into continuous biomarker monitoring platforms. Our CardioID software detects early physiologic changes associated with heart failure deterioration. Operating at the intersection of digital health and cardiovascular medicine, GPx plans its first FDA submission in Q2 2026.
-
Sean Matsuoka
CEO & Co-Founder
-
Sidhant Jena
Founding Advisor
Samay
Samay is building the foundation for Infrastructure-Independent Spirometry — delivering FEV1, FVC, and air trapping from a light-effort chest wearable, reaching the small airways traditional tests miss. Better patient phenotyping, continuous monitoring, and more sensitive drug efficacy detection. We aren’t improving a test. We’re replacing 170 years of limitation.
-
Maria Artunduaga
Founder & CEO
Nine Diagnostics
Nine Diagnostics is redefining how treatment effectiveness is determined. Rather than waiting months for imaging or clinical progression, our AI-enabled blood tests detect rapid biological response from a simple blood draw. This enables faster clinical decisions, improves patient stratification, and supports more efficient drug development. We are building the foundation for a more responsive, feedback-driven…
-
Dr. Freddy T. Nguyen, MD, PhD
CEO & Co-Founder
-
Dr. Daniel A. Heller, PhD
CSO & Co-Founder
-
Dr. Mijin Kim, PhD
Co-Founder & Scientific Advisor
Harmonia Therapeutics
Harmonia Therapeutics is an oncology company developing DUET-ADCs™, a novel class of logic-gated antibody-drug conjugates. Our platform utilizes a dual-key mechanism requiring two signals to activate the drug exclusively inside cancer cells. By eliminating systemic toxicity, Harmonia aims to dramatically widen the therapeutic window for aggressive cancers.
-
Brett Tingley, PhD
CEO & Co-Founder
-
Mark Grinstaff, PhD
Advisor & Co-Founder
GT Biosciences, Inc.
GT Biosciences is a techbio company developing scalable cell-type-specific precision therapies. The company is building Deliveromics, a spatial biology and AI-powered platform for high-throughput in vivo screening and predictive design of targeted delivery vehicles such as ligand-conjugated lipid nanoparticles. We are creating cell-type-specific delivery solutions for the brain, immune system, and other tissues.
-
Dr. Tay Won Shin
Co-Founder & CEO
-
Dr. Chi Zhang
Co-Founder & CSO
-
Prof. Edward Boyden
Scientific Co-Founder & Advisor
Laurel Biotherapeutics
Laurel Biotherapeutics is building a new class of precision biologics at the intersection of cardiovascular disease and serious comorbid conditions affecting millions of patients. At Laurel, we focus on restoring protective biological signaling pathways that regulate cardiac and systemic health. Our initial program in cardiorenal disease leverages targeted nanobody therapeutics to activate the natriuretic peptide…
-
Tatiana Blanchard, PhD
CEO/Co-Founder
-
Matt Therkelsen, PhD
President/Co-Founder
-
Michael White, PhD
CSO/Co-Founder
Othelium Therapeutics
Othelium Therapeutics is developing first-in-class biologics to restore endothelial function and treat microvascular disease and heart failure.
-
Emily Ricq, PhD
CEO
-
Tim Hla, PhD
Investigator, Vascular Biology Program, Boston Children's Hospital; Chair and Professor, Patricia K. Donohoe, Department of Surgery, Harvard Medical School
Augment Biologics
Augment Biologics, a platform-enabled therapeutics company, is unlocking new possibilities in drug surface design using our landmark discovery in glycoengineering, which we call GlycoTemplating. Led by technological founders and experienced entrepreneurs, we are creating a new class of GlycoTemplated biologics. The problem is that glycans matter, but glycoengineering is hard. By genetically encoding the desired…
-
Benjamin P. Kellman, PhD
CEO and Co-Founder
-
Nathan E. Lewish, PhD
Scientific Advisor and Co-Founder
-
Samuel W. Canner, PhD
Founding AI Scientist
-
Caitlin Brown, PhD
Business Development Advisor
NeuroSkye Therapeutics
NeuroSkye Therapeutics is a translational biotechnology company developing human BBB and blood-tumor-barrier (BTB) functional diagnostic platforms to inform treatment decisions in brain tumors. Operating at the intersection of neuro-oncology, precision diagnostics, and translational medicine, NeuroSkye addresses a critical gap in therapy selection by evaluating drug delivery feasibility across the BBB/BTB, enabling more informed, delivery-based clinical…
-
Choi-Fong Cho, PhD
Founder
Dxcover
Dxcover is a clinical-stage diagnostics company developing AI-enabled liquid biopsy tests for earlier cancer detection. Its proprietary platform combines infrared spectroscopy with AI to analyse the full biochemical signature of blood, capturing both tumour and host-response signals. With one of the largest spectral multiomic datasets globally and the first regulatory approval of its kind, Dxcover…
-
Matthew J. Baker, PhD, FRSC
CEO
-
Holly Butler, PhD
CTO
-
David Palmer, PhD
CSO
Tinker Therapeutics
Tinker is a biopharmaceutical company engineering next-generation multimeric siRNA and ASO RNA medicines. Our proprietary FORGE™ platform creates chemically optimized, fused oligonucleotides capable of modulating multiple genetically validated targets in a single therapeutic construct, leveraging AI-enabled computational screening and design methods. We focus on complex polygenic neurological and retinal disorders where multi-targeting can uniquely address…
-
Claes Wahlestedt, PhD, MD
CEO, Co-Founder
-
Jack Stahl, PhD
CSO, Co-Founder
-
Arthur Polk
CFO, Co-Founder